MTOR and prostate cancer: Recently, Chu et al. delineated activation of TREM1/CCL2 and AKT/mTOR/STAT3 as an additional mechanism to ASS1 re-expression, mediating ADI-PEG20 resistance in breast and prostate cancer cells [53].